Lupin launches drugs to cure leukaemia
Pharma major Lupin informed the bourses that it has launched Imatinib Mesylate Tablets, 100 mg (base) and 400 mg (base). It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells.
The said medicine is the generic version of Novartis Pharmaceuticals Corporation’s (Novartis) Gleevec Tablets, 100 mg and 400 mg. It is used in the treatment of certain types of cancer like leukaemia, chronic myeloid leukaemia, gastrointestinal stromal tumours, etc. It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells.
As per IQVIA data, the said drug had annual sales of US$548 million in the 12-month period ending May 2019 in the US market.
Lupin is engaged in developing and delivering branded and generic formulations. It also further produces biotechnology products and APIs globally. It is also a major player in Cardiovascular, Diabetology, Asthma, Pediatric, CNS, Gl, Anti-Infective and NSAID space.
On Tuesday, the stock opened at Rs. 734 per share and made an intraday low of Rs. 730.85 and made an intraday high of Rs. 752.60 on the BSE. The stock had hit its 52-week high of Rs. 986 on September 10, 2018 and its 52-week low of Rs. 697.30 on June 19, 2019 on the BSE.